Calaspargase pegol-mknl (trade name Asparlas) is a drug for the treatment of acute lymphoblastic leukemia (ALL). It is approved by the Food and Drug Administration for use in the United States as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients aged 1 month to 21 years.
Calaspargase pegol is an engineered protein consisting of the E. coli-derived enzyme L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (pegol). The L-asparaginase portion hydrolyzes L-asparagine to L-aspartic acid depriving the tumor cell of the L-asparagine it needs for survival. The conjugation with the pegol group increases the half-life of the drug making it longer acting.
- "FDA approves longer-acting calaspargase pegol-mknl for ALL" (Press release). Food and Drug Administration. December 20, 2018.
- "Calaspargase pegol-mknl". NCI Drug Dictionary. National Cancer Institute.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|